Alternative Cell Type and in Situ Cell Therapies

• 127 · PDF Riboflavin biosynthesis byproducts increase the vulnerability of cancer to adoptive MAIT TCR-engineered T-cell transfer Ying Zheng, Pakhi Birla, Wanting Shan, Samuel Huang, Franck Housseau, Drew Pardoll
• 128 · PDF Synthetic reprogramming of gammadelta CAR T cells with the LTBR gene optimizes function in the TME and overcomes effector limitations Mitchell S. Wang, Ivan Reyes-Torres, Kristen C. Vogt, Caroline K. Hanlon, Ashley N. Thornal, Maria Guarino, Eric M. Johnson, Mark P. Roberto, Navamallika G. Reddy, Miao Chen, Theodore Giavridis, Mateusz Legut
• 130 · PDF Expanding the ACT paradigm: B cell engineering via spherical nucleic acids for cancer immunotherapy Maryam Balibegloo, Yingying Li, Abu Baker, Jie Fan, Ping Xie, Mi Ran Choi, Catalina Lee Chang, Vinzenz Mayer, Michael Evangelopoulos, Chad A. Mirkin, Bin Zhang
• 131 · PDF Enhanced feeder-free expansion, survival, potency and post manufacture stability of NK cells for CAR-NK therapies using human platelet lysate Vanesa Alonso-Camino, Andrew Sullivan
• 132 · PDF Improving effector cells for CAR-NK immunotherapy against colorectal cancer Marco Cortese, Alice D'Andrea, Alfonso Navarro Zapata, Sahar Taebi, Consalvo Petti, Enzo Medico
• 133 · PDF NEO-201-recognized truncated Core 1 O-glycans represent a new target for CAR-NK therapy in AML Joseph A. Clara, Nile Liu, Mala Chakraborty, Kwong Y. Tsang, Massimo Fanitni, Philip M. Arlen, Richard W. Childs
• 134 · PDF Anti-tumor activity of engineered iPSC-derived NK cells against metastatic uveal melanoma cells Nadia Anikeeva, Tong Zhang, Sota Deguchi, Sergei Koshkin, Masashi Yamada, Kouichi Tamura, Hironobu Kimura, Vitali Alexeev, Yuri Sykulev, Takami Sato, Mizue Terai
• 135 · PDF Memory-like NK cell targeting to CD123 and CD33 improves killing of acute myeloid leukemia Emily Phillips, Lyra Morina, Lynne Marsala, Wilbur Song, Michelle Becker-Hapak, Yoojin Ahn, Sushanth Pureti, Elizabeth Juarez Diaz, Sadia Afrin, Pamela Wong, Jennifer Tran, Joseph Rueve, Allison Burdi, Nancy Marin, Melissa Marie Berrien-Elliott, Martin Felices, Jeffrey S. Miller, Todd A. Fehniger
• 136 · PDF Surface engineered-NK/trastuzumab cells as a novel immunotherapy for HER2-low breast cancer Maria Jose Godoy Calderon, Manali Patwardhan, Shruti Rodrigues, Saanvi Sethi, Eric Gauchat, Vk Gadi
• 137 Harnessing allogeneic CAR‑iNKT cells for next‑generation treatments in oncology and autoimmunity Yuhua Wan, Dexian Quan, Feng Xu, Yuzhu Cui, Jian Hua, Jingyu Li, Hua Zhang
• 138 · PDF Generation of scalable off-the-shelf iNKT therapies John J. Swain, Eoin C. Whelan, Chiquita Hanindya, Peter Keller, Antonia Rotolo
• 139 · PDF Functional profiling of an allogeneic NK cell therapy product in NSCLC patient-derived organotypic tumor spheroids Chunxiao Cui, Anthony Attardo, Mei Rosa Ng, Yana Wang, Michael A. Perricone
• 140 · PDF Allogeneic CAR-iNKT cell therapy targeting CLDN18.2-positive gastric and pancreatic cancers Clinton M. Heinze, Elisa Landoni, Michelle Ferguson, Nicole van der Weerden, Robson Dossa, Simon Poon, Kelvin Yip, Jacqui Cumming, Alfie Baker, Sandford Sarah, Michael J. Baker, Barbara Savoldo, Gianpietro Dotti
• 141 · PDF Selecting cord blood-derived NK cells enriched in mature subsets optimizes CAR-NK cell-based anti-tumor therapy Ye Ethan Li, Huihui Fan, Rafet Basar, Wilson Jeffrey, Patrick Zhang, Katayoun Rezvani
• 142 · PDF A universal multi-receptor NK cell platform engineered for synergistic combination with antibody and T-cell engager therapies Rafet Basar, Bin Liu, Nadima Uprety, Francia Reyes Silva, Rejeena Shrestha, Sunil Acharya, May Daher, Ana K. Nunez Cortes, Deqiang Zhang, Bingqian  Hu, Silvia Tiberti, Madison Moore, Ye Ethan Li, Pinghua Liu, Hila Shaim, Jeong-Min Park, Mecit  Kaplan, Xingliang  Guo, Mayra Shanley, Ping Li, Paul Lin, Pinaki Banerjee, Huihui Fan, Patrick Zhang, Enli Liu, Seema Rawal, Elizabeth Joan Shpall, Katayoun Rezvani
• 143 · PDF Enhancing gammadelta CAR T cell function through alternative CD3 cytoplasmic domains Philipp Metzger, Marina Zintchenko, Susana Minguet, Cynthia Obodozie, Holger Weber
• 144 · PDF In vivo CAR mRNA engineering of both adaptive and myeloid cells enables potent anti-tumor control of solid cancers Junming Tong, Moore Chen, Kevin Sek, Meghan Harris, Jerome Chal, Colin Pouton, Angus Johnston, Daniel Getts, Robert Hofmeister, Phil Darcy, Jian Ding
• 145 · PDF CD8 nanobody-targeted lipid nanoparticles encapsulating CD13 nanoCAR circular RNAs for in situ CAR-T cell eradication of acute myeloid leukemia Wilson Huang, Diva Chen, Yun-Chin Chou, Tsung-Chih Chen, Chia-Jen Wu
• 146 · PDF In vivo lentiviral CAR-T gene delivery demonstrates high specificity and potent anti-tumor activity in a humanized B cell lymphoma model Ilian Radichev, Devin Stranford, Hailey Edelstein, Oanh Pham, Destanie Rose, Jiwon Yang, Mahdy Yassine, Henry Schirmer, Teresa Nikolich, Joshua Leonard, James Keck, Matteo Stoppato
• 147 · PDF A multipronged approach to improve gene delivery efficiency for in vivo CAR-T using CD3 and CD7 retargeted LVVs Longshan Liu, Cheng Luo, Yangyang Tang, Lianqu Li, Hai Huang, Mangmang Li, Yu Liang
• 148 · PDF In vivo CAR-T T-LNP system (GT801) drives potent B cell depletion and clinical feasibility in hematologic and autoimmune conditions Jingwei Sun, Xi Zhu, Jiahui Jin, Yiyang Tan, Liang Lin, Zhao Xu, Jingman Wang, Dalang Li, Hong Chen, Jiaming Ren, Jun Cui, Jing Yu, Pin Wang, Yarong Liu
• 149 · PDF Erythrocyte-mediated mRNA delivery enables in vivo generation of CAR-myeloid cells for cancer immunotherapy Xiaoqian Nie, Yuehua Liu, Xiaofei Gao
• 150 · PDF T-cell specific transcriptional control eliminates CAR-mediated off-target transduction by CD3-retargeted lentiviral vectors, enabling safe in vivo generation of potent alphaBCMA-CAR T cells Karina Krotova, Nandakumar Packiriswamy, MD Yeashin Gazi, Collin Gwilt, Chia-Hsuan Chin, Ajay Kumar, Aaron Hawkes, Gopal Naik Nenavath, Thipparat Suwanmanee, Darren Phung, Luke W. Breigenzer, Timothy Carey, Christian Kinney, Hamid Salimi, Patrycja Lech, Kah-Whye Peng, Stephen Russell
• 151 · PDF Combination of cytokines, PM21-particle stimulation, and TGF-beta conditioning results in Natural Killer cells with enhanced cytotoxicity and infiltration of solid tumors Jeremiah L. Oyer, Tayler J. Croom-Perez, Javier A. Rivera-Huertas, Brian P. Tullius, Alicja J. Copik
• 152 · PDF Toward an in vivo anti-BCMA/CD19 CAR-T cell treatment of B cell-mediated autoimmune diseases Alexander J. Najibi, Denise Wong, Jeff Wood, Tharani Sivanandam, Han K. Lee, Josue Figueroa, Kelly Nichols, Yao Wei, Emily T. Beura, Shannon Grande Contrastano
• 153 Improvement of monoclonal antibody therapy against cancer through engineering stem cell-derived CD16-enhanced universal NKT cells Yan-Ruide Li, Yichen Zhu, Yanqi Yu, Lili Yang
• 154 · PDF Robust engraftment of human gammadelta T cells in humanized NSG TM -SGM3-IL-15 × MHC I/II double knockout mice for the evaluation of gammadelta T cell-based therapeutics Kevin Tsai, Beau Parry, Destanie Rose, James G. Keck, Li-Chin Yao

在完整检索应用中浏览本分会场 →